Tag: Rare cancer precision medicine

Home / Rare cancer precision medicine

Categories

Repotrectinib has received accelerated approval from the USFDA for adult and pediatric patients with NTRK gene fusion-positive solid tumors

  June 2024: The Food and Drug Administration (FDA) has given accelerated approval to repotrectinib (AUGTYRO, Bristol-Myers Squibb Company) for the treatment of solid tumors in adult and pedia...
rare-cancer-precision-medicine

Scan the code